Vaccine therapy for stage II colon cancer after surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized vaccine made from your own tumor cells to see if it can prevent colon cancer from coming back after surgery. It is for people with stage II colon cancer that was completely removed and no signs of cancer elsewhere.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II colon cancer (tumor has grown into the colon wall but not spread to lymph nodes or distant sites).
- You had surgery to remove the cancer, and no cancer remains.
- Your CEA level (a blood marker for cancer) is normal after surgery, or if it was high before surgery, it returned to normal within 21 days.
- You have not had chemotherapy or radiation therapy for this cancer before.
- You have not had any other cancer in the past, except for certain skin cancers or early cervical cancer that were fully treated.
- You have only one colon cancer tumor (not multiple separate tumors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial tests whether a personalized vaccine—made from your own immune cells mixed with your own tumor material—can help prevent colorectal cancer from coming back after curative surgery. It may help your immune system recognize and fight any remaining cancer cells.
This trial tests a custom-made vaccine designed from your tumor's genetic material. The vaccine is given alongside standard chemotherapy and an immunotherapy drug to try to prevent the cancer from coming back. It is for people with stage 3 colorectal cancer that has been fully removed by surgery and has certain high-risk features.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
Hear when a new Stage II Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.